Search





Search





Markets
/
Stocks
/
nasdaq-txg
/

10X Genomics Inc

TXG

Add to Watchlist

20.500USD

-1.100-5.09%

Close 05/11, 16:00（ET）Quotes delayed by 15 min

2.59BMarket Cap

LossP/E TTM



10X Genomics Inc

20.500

-1.100-5.09%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of 10X Genomics Inc

Currency: USD Updated: 2026-05-08

Key Insights

10X Genomics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 60 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 23.29.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

10X Genomics Inc's Score

Industry at a Glance

Industry Ranking

60 / 206

Overall Ranking

153 / 4494

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

10X Genomics Inc Highlights

StrengthsRisks

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.

Undervalued

The company’s latest PE is -124.27, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 133.89M shares, decreasing 5.83% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 2.78K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.35.

Analyst Rating

Based on 18 analysts

Buy

Current Rating

24.643

Target Price

+14.09%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-08

The current financial score of 10X Genomics Inc is 7.17, ranking 82 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 150.84M, representing a year-over-year decrease of 2.61%, while its net profit experienced a year-over-year decrease of 60.80%.

Score

Industry at a Glance

Previous score

7.17

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

4.35

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.38

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.95

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.17

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

10X Genomics Inc's Company Valuation

Currency: USD Updated: 2026-05-08

The current valuation score of 10X Genomics Inc is 8.21, ranking 38 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -124.27, which is -95.56% below the recent high of -5.52 and -3.80% above the recent low of -128.98.

Score

Industry at a Glance

Previous score

8.21

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 60/206

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-08

The current earnings forecast score of 10X Genomics Inc is 7.11, ranking 151 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 16.00, with a high of 20.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

7.11

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 18 analysts

Buy

Current Rating

24.643

Target Price

+14.09%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

116

Total

Median

Average

Company name

Ratings

Analysts

10X Genomics Inc

TXG

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-08

The current price momentum score of 10X Genomics Inc is 6.86, ranking 101 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 25.52 and the support level at 18.61, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.10

Change

-0.24

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.480

Neutral

RSI(14)

42.425

Neutral

STOCH(KDJ)(9,3,3)

45.480

Sell

ATR(14)

1.496

High Vlolatility

CCI(14)

-122.737

Sell

Williams %R

75.752

Sell

TRIX(12,20)

-0.060

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

21.854

Sell

MA10

21.697

Sell

MA20

22.731

Sell

MA50

21.508

Sell

MA100

20.339

Buy

MA200

17.215

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-08

The current institutional shareholding score of 10X Genomics Inc is 10.00, ranking 1 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 112.60%, representing a quarter-over-quarter increase of 4.13%. The largest institutional shareholder is The Vanguard, holding a total of 12.85M shares, representing 10.81% of shares outstanding, with 8.23% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

ARK Investment Management LLC

Star Investors

12.67M

+6.56%

Fidelity Management & Research Company LLC

9.75M

+35.17%

BlackRock Institutional Trust Company, N.A.

8.29M

+6.63%

Amova Asset Management Co., Ltd.

5.38M

Sumitomo Mitsui Trust Bank, Limited

5.49M

+2.06%

Quantinno Capital Management LP

4.67M

+33.64%

Geode Capital Management, L.L.C.

2.79M

+2.90%

Jacobs Levy Equity Management, Inc.

2.64M

-10.45%

Risk Assessment

Currency: USD Updated: 2026-05-08

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of 10X Genomics Inc is 4.85, ranking 93 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 2.05. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.